cell therapy Archives -

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million

Vertex buys diabetes cell therapy rival ViaCyte for $320m

https://pharmaphorum.com/news/vertex-buys-diabetes-cell-therapy-rival-viacyte-for-320m/

News/ News/ R&D

Astellas teams up with UK biotech Mogrify on hearing loss project

Phil Taylor Astellas, cell therapy, hearing loss, Mogrify, otology, partnering, Regenerative medicine 0 Comment

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy

Astellas teams up with UK biotech Mogrify on hearing loss project

https://pharmaphorum.com/news/astellas-teams-up-with-uk-biotech-mogrify-on-hearing-loss-project/

Market Access/ News/ News/ News/ Oncology

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Phil Taylor CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta 0 Comment

Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of

Kymriah is first CAR-T cleared for follicular lymphoma in EU

https://pharmaphorum.com/news/kymriah-is-first-car-t-cleared-for-follicular-lymphoma-in-eu/

News/ News/ News/ Oncology/ R&D

Nkarta leaps on early CAR-NK data in blood cancers

Phil Taylor acute myeloid leukaemia, car-nk, cell therapy, Haematology, immuno-oncology, lymphoma, Nkarta, Oncology 0 Comment

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be

Nkarta leaps on early CAR-NK data in blood cancers

https://pharmaphorum.com/news/nkarta-leaps-on-early-car-nk-data-in-blood-cancers/

Events/ Events

3rd Gamma Delta T Therapies Summit

Jessica Durston cell therapy, gamma delta, natural killer cells, pharma, R&D 0 Comment

The Only Industry-Specific Event on γδT Therapies

3rd Gamma Delta T Therapies Summit

https://pharmaphorum.com/events/3rd-gamma-delta-t-therapies-summit/

News/ News/ Oncology

Bayer backs KRAS TCR player Affini-T in $175m financing

Phil Taylor Affini-T, cell therapy, immuno-oncology, KRAS, Oncology, p53, TCR 0 Comment

Bayer’s venture capital unit has co-led a $175 million investment in Affini-T that will be used to take

Bayer backs KRAS TCR player Affini-T in $175m financing

https://pharmaphorum.com/news/bayer-backs-kras-tcr-player-affini-t-in-175m-financing/

News/ News/ Oncology

BMS cuts $3.15bn deal with Century for cancer cell therapies

Phil Taylor acute myeloid leukaemia, Bristol-Myers Squibb, cell therapy, Century Therapeutics, Haematology, immuno-oncology, multiple myeloma, Oncology 0 Comment

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP

BMS cuts $3.15bn deal with Century for cancer cell therapies

https://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/

News/ News/ Oncology

Milestone as EMA starts review of Atara’s ‘off-the-shelf’ cell therapy

Phil Taylor allogeneic, Atara, cell therapy, immuno-oncology, Oncology, Pierre Fabre, tabelecleucel 0 Comment

Atara Biotherapeutics’ tabelecleucel (tab-cel) has become the first ‘allogeneic’ cell therapy – in other words one which doesn’t

Milestone as EMA starts review of Atara’s ‘off-the-shelf’ cell therapy

https://pharmaphorum.com/news/milestone-as-ema-starts-review-of-ataras-off-the-shelf-cell-therapy/

News/ News/ Oncology

Blackstone revs up Autolus’ CAR with $250m fuel injection

Phil Taylor acute lymphoblastic leukaemia, Autolus, Blackstone, CAR-T therapies, cell therapy, financing, immuno-oncology, Oncology 0 Comment

Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus

Blackstone revs up Autolus’ CAR with $250m fuel injection

https://pharmaphorum.com/news/blackstone-revs-up-autolus-car-with-250m-fuel-injection/

Trending

cell therapy

Login